PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Perampanel

Drugs in development · updated 30 October 2026

Perampanel: clinical trials and development status

Other names and codes: Fycompa

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 23 July 2012

As of 30 October 2026 Perampanel is in 5 active clinical trials (recruiting or ongoing, phases I–III) for 11 diseases. The most advanced phase is II.

5Active trials
IIMost advanced phase
11Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Perampanel and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Major depressive disorderII2NCT05786066
Post-traumatic stress disorderII2NCT05786066
SeizuresII2NCT06401707
Bipolar disorderII1NCT05786066
Depressive disorderII1NCT05786066
EpilepsyII1NCT04015141
Heart ArrestII1NCT06401707
Status epilepticusII1NCT06401707
Suicidal ideationII1NCT05786066
SuicideII1NCT05786066
GlioblastomaEarly I1NCT07284069

Everything on Perampanel

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch